微型月季通过调节肠道菌群、抑制TLR4、增强紧密连接蛋白和促进代谢来缓解小鼠炎症性肠病

Miniature rose alleviates inflammatory bowel disease in mice by modulating gut microbiota, inhibiting TLR4, enhancing tight junction proteins, and promoting metabolism.

作者信息Jiaying Wu, Xuwen Mao
PMID41568049
发布时间2026-01-16
DOI10.3389/fmicb.2025.1721294

实验完整度

包含DSS诱导小鼠结肠炎模型、16S rRNA测序、非靶向代谢组学、免疫组化、ELISA等多层级验证,且明确功能与机制验证。

主要模型

C57BL/6J小鼠DSS诱导结肠炎模型 肠道菌群(粪便样本) 小鼠结肠组织

重点核对

DSS诱导浓度:3% DSS自由饮用10天 给药剂量:MR低、中、高剂量分别为25、50、100 mg/kg 阳性对照:地塞米松(DEX)0.4 mg/kg 8周龄雄性C57BL/6J小鼠,体重20-24g 检测指标:TLR4、TLR9、OCC、ZO-1表达,肠道通透性(FITC-DEX)

摘要

Introduction: Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder of the gastrointestinal tract. Its pathogenesis is complex and not fully understood, so it remains incurable. Traditional Chinese medicine (TCM) attracts attention as a potential option. It offers multi-target actions. This study investigated the protective effects of an aqueous extract of Miniature Rose (MR), a medicinal plant from Xinjiang, in a dextran sulfate sodium (DSS)-induced murine model of IBD. We focused on gut microbiota, intestinal barrier integrity, and metabolic homeostasis.Methods: IBD was induced in mice by DSS, followed by intervention with different doses of aqueous MR extract. A multi-faceted approach incorporating 16S rRNA sequencing, non-targeted metabolomics, immunohistochemistry, and ELISA was used to evaluate the effects of MR on gut microbiota composition, fecal metabolic profiles, intestinal barrier protein expression, and the expression of the inflammatory proteins TLR4 and TLR9.Results: Treatment with aqueous MR extract markedly alleviated DSS-induced colitis. MR improved intestinal barrier integrity by upregulating the tight junction proteins Occludin (OCC) and Zonula Occludens-1 (ZO-1), while concurrently downregulating TLR4 and TLR9. MR administration also markedly modulated the gut microbiota, increasing the relative abundance of beneficial genera (Bacteroides and Alloprevotella) and decreasing the abundance of the pathobiont Erysipelatoclostridium. In addition, MR mitigated the metabolic dysregulation observed in DSS-induced colitis.Conclusion: MR ameliorates DSS-induced colitis through a multifaceted mechanism that involves coordinated regulation of the gut microbiota, restoration of the intestinal barrier, inhibition of inflammatory protein expression, and correction of metabolic dysregulation. These findings highlight the potential of MR as a multi-target therapeutic candidate and provide an experimental basis for its further preclinical and clinical evaluation in IBD.

实验结论

提炼研究问题、关键发现与证据,快速把握文章的核心贡献。

研究问题
微型月季水提物能否通过调节肠道菌群、抑制TLR4/TLR9、增强紧密连接蛋白和改善代谢来缓解DSS诱导的结肠炎?
核心机制
MR通过调节肠道菌群组成(增加有益菌Bacteroides和Alloprevotella,减少致病菌Erysipelatoclostridium),抑制TLR4/TLR9介导的炎症信号,上调紧密连接蛋白OCC和ZO-1,并纠正代谢紊乱,从而改善肠道屏障功能。
主要证据
DSS诱导的结肠炎小鼠模型;16S rRNA测序显示MR-H组菌群多样性恢复,有益菌丰度增加;免疫组化显示TLR4/TLR9下调、OCC/ZO-1上调;ELISA显示促炎因子(TNF-α、IL-6等)降低;代谢组学显示关键代谢物改变。
研究意义
MR作为多靶点治疗候选药物,具有治疗IBD的潜力,为其临床前和临床评估提供实验依据。

研究路径

按研究推进顺序梳理实验设计、验证步骤与关键观察。

1

建立DSS诱导的结肠炎模型及MR干预

验证MR对DSS诱导结肠炎的保护作用

雄性C57BL/6J小鼠随机分为Control、DSS、DEX、MR-L、MR-M、MR-H组,DSS组自由饮用3% DSS溶液10天,MR组每日灌胃相应剂量MR提取物,DEX组腹腔注射地塞米松,对照组和DSS组给予无菌水。每日记录体重、粪便特征,评估DAI评分。

2

评估肠道屏障功能和炎症指标

检测MR对肠道通透性和炎症因子的影响

通过FITC-DEX灌胃后测定血浆荧光强度评估肠道通透性;测量结肠长度和重量;ELISA检测血清TNF-α、IL-6、CXCL-1和MPO水平;结肠组织H&E染色观察病理变化。

3

检测肠道屏障蛋白和TLR表达

验证MR对紧密连接蛋白和TLR4/TLR9表达的影响

采用免疫组化染色检测结肠组织中TLR4、TLR9、OCC和ZO-1的表达,并用ImageJ软件定量分析。

4

分析肠道菌群组成和多样性

探究MR对肠道菌群结构和多样性的调节作用

提取粪便微生物DNA,扩增16S rRNA V3-V4区,Illumina MiSeq测序,进行α多样性分析、门/属水平组成分析、LEfSe差异分析等。

5

非靶向代谢组学分析

评估MR对粪便代谢谱的影响

提取粪便代谢物,采用UPLC-ESI-MS/MS进行非靶向代谢组学分析,鉴定差异代谢物,并进行KEGG通路富集分析。

6

关联分析菌群与代谢物及病理指标

探讨菌群变化与代谢物、炎症指标和屏障功能之间的相关性

利用RDA和相关性热图分析关键菌属(如Bacteroides、Alloprevotella、Erysipelatoclostridium)与差异代谢物、TLR表达、紧密连接蛋白和炎症因子的相关性。

研究方法

按研究目的归类文中使用的方法,便于定位所需技术。

验证样本或模型特征
验证细胞功能变化
验证免疫效应

产品清单

实验环节名称品牌货号
葡聚糖硫酸钠Macklin--
地塞米松Shanghai Yuanye Biotechnology Co., Ltd.--
ZO-1抗体Thermo Fisher Scientific--
OCC抗体Thermo Fisher Scientific--
TLR4抗体Novus Biologicals--
TLR9抗体Bioss Antibodies--
异硫氰酸荧光素-葡聚糖----
ELISA试剂盒Nanjing Jiancheng Bioengineering InstituteTNF-α,
Illumina MiSeq平台IlluminaPE
Acquity UPLC HSS T3色谱柱Waters2.1×100
ImageJ----
GraphPad Prism--version
MS-DIAL--ver.
Wekemo Bioincloud----
Canoco 5----

关键环节

汇总复现实验时建议重点确认的条件及原文阅读提示。

环节核对要点
动物模型建立
小鼠品系、性别、年龄、体重;DSS浓度、给药途径和持续时间
阅读提示:Materials and methods, 2.2 Animal husbandry and ethical statement; 2.3 IBD model induction and treatment protocol
给药干预
MR提取物制备方法、剂量、给药途径;阳性对照DEX剂量和给药途径
阅读提示:Materials and methods, 2.1 Drugs and reagents; 2.3 IBD model induction and treatment protocol
肠道通透性检测
FITC-DEX剂量、禁食时间、灌胃后采血时间、血浆制备方法、荧光检测条件
阅读提示:Materials and methods, 2.4 Intestinal permeability assay
分子表达检测
抗体来源和稀释比例;免疫组化染色步骤和定量方法;ELISA试剂盒品牌和检测指标
阅读提示:Materials and methods, 2.6 ELISA assay; 2.7 Immunohistochemistry
肠道菌群分析
粪便DNA提取方法;16S rRNA V3-V4区扩增引物和测序平台;生物信息分析流程和数据库版本
阅读提示:Materials and methods, 2.8 Fecal microbial DNA extraction; 2.9 Illumina sequencing; 2.10 Bioinformatic analysis
代谢组学分析
粪便样品量;代谢物提取溶剂和条件;UPLC-MS/MS参数(色谱柱、流动相、梯度程序、质谱参数)
阅读提示:Materials and methods, 2.11 Untargeted metabolomic analysis